Insulin-like growth factor-I and insulin-like growth factor binding protein-3 in Alzheimer's disease. Duron, E., Funalot, B., Brunel, N., Coste, J., Quinquis, L., Viollet, C., Belmin, J., Jouanny, P., Pasquier, F., Treluyer, J., Epelbaum, J., le Bouc, Y., & Hanon, O. The Journal of Clinical Endocrinology and Metabolism, 97(12):4673–4681, December, 2012. doi abstract bibtex CONTEXT: Few large studies have been conducted to assess the relationship between circulating IGF and late-life cognition. OBJECTIVE: The aim of the study was to assess the relationship between IGF-I and IGF binding protein-3 (IGFBP-3) serum levels and cognitive impairment, including Alzheimer's disease (AD). METHODS: In this multicentric cross-sectional study, 694 elderly subjects (218 men, 476 women; 78.6 ± 6.7 yr old) were included; 481 had memory complaints and were diagnosed, after comprehensive cognitive assessment, with AD (n = 224) or mild cognitive impairment (MCI) (n = 257). The control group was comprised of 213 subjects without memory complaint and with normal cognition (recruited among patients' caregivers). IGF-I and IGFBP-3 serum levels were determined by ELISA. RESULTS: IGF-I and IGFBP-3 serum levels were significantly associated with cognitive status in men (IGF-I, 137 ± 69 ng/ml for AD vs. 178 ± 88 ng/ml for MCI and 172 ± 91 ng/ml for controls, P = 0.01; IGFBP-3, 3675 ± 1542 ng/ml for AD vs. 4143 ± 1828 ng/ml for MCI and 4488 ± 1893 ng/ml for controls, P = 0.04). In women, IGFBP-3 was significantly associated with cognitive status (3781 ± 1351 ng/ml for AD vs. 4190 ± 1408 ng/ml for MCI and 4390 ± 1552 ng/ml for controls; P \textless 0.001), but no significant differences between groups for IGF-I occurred. After adjustment for confounding variables (age, educational level, body mass index, diabetes, apolipoprotein E ε4 status), logistic regression indicated that IGF-I [odds ratio (95% confidence interval) = 0.48 (0.26-0.88)] and IGFBP-3 [odds ratio (95% confidence interval) = 0.71 (0.52-0.97)] serum levels were independently associated with AD in men, but not in women. CONCLUSIONS: We report a significant association between low IGF-I and IGFBP-3 serum levels and AD in men, but not in women.
@article{duron_insulin-like_2012,
title = {Insulin-like growth factor-{I} and insulin-like growth factor binding protein-3 in {Alzheimer}'s disease},
volume = {97},
issn = {1945-7197},
doi = {10.1210/jc.2012-2063},
abstract = {CONTEXT: Few large studies have been conducted to assess the relationship between circulating IGF and late-life cognition.
OBJECTIVE: The aim of the study was to assess the relationship between IGF-I and IGF binding protein-3 (IGFBP-3) serum levels and cognitive impairment, including Alzheimer's disease (AD).
METHODS: In this multicentric cross-sectional study, 694 elderly subjects (218 men, 476 women; 78.6 ± 6.7 yr old) were included; 481 had memory complaints and were diagnosed, after comprehensive cognitive assessment, with AD (n = 224) or mild cognitive impairment (MCI) (n = 257). The control group was comprised of 213 subjects without memory complaint and with normal cognition (recruited among patients' caregivers). IGF-I and IGFBP-3 serum levels were determined by ELISA.
RESULTS: IGF-I and IGFBP-3 serum levels were significantly associated with cognitive status in men (IGF-I, 137 ± 69 ng/ml for AD vs. 178 ± 88 ng/ml for MCI and 172 ± 91 ng/ml for controls, P = 0.01; IGFBP-3, 3675 ± 1542 ng/ml for AD vs. 4143 ± 1828 ng/ml for MCI and 4488 ± 1893 ng/ml for controls, P = 0.04). In women, IGFBP-3 was significantly associated with cognitive status (3781 ± 1351 ng/ml for AD vs. 4190 ± 1408 ng/ml for MCI and 4390 ± 1552 ng/ml for controls; P {\textless} 0.001), but no significant differences between groups for IGF-I occurred. After adjustment for confounding variables (age, educational level, body mass index, diabetes, apolipoprotein E ε4 status), logistic regression indicated that IGF-I [odds ratio (95\% confidence interval) = 0.48 (0.26-0.88)] and IGFBP-3 [odds ratio (95\% confidence interval) = 0.71 (0.52-0.97)] serum levels were independently associated with AD in men, but not in women.
CONCLUSIONS: We report a significant association between low IGF-I and IGFBP-3 serum levels and AD in men, but not in women.},
language = {eng},
number = {12},
journal = {The Journal of Clinical Endocrinology and Metabolism},
author = {Duron, Emmanuelle and Funalot, Benoît and Brunel, Nadège and Coste, Joel and Quinquis, Laurent and Viollet, Cécile and Belmin, Joel and Jouanny, Pierre and Pasquier, Florence and Treluyer, Jean-Marc and Epelbaum, Jacques and le Bouc, Yves and Hanon, Olivier},
month = dec,
year = {2012},
pmid = {23015654},
keywords = {Aged, Alzheimer Disease, Humans, Cognition, Female, Male, Neuropsychological Tests, Cross-Sectional Studies, Aged, 80 and over, Apolipoproteins E, Genotype, Memory, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I},
pages = {4673--4681}
}
Downloads: 0
{"_id":"sDTM35tMtCrb39Rr4","bibbaseid":"duron-funalot-brunel-coste-quinquis-viollet-belmin-jouanny-etal-insulinlikegrowthfactoriandinsulinlikegrowthfactorbindingprotein3inalzheimersdisease-2012","authorIDs":[],"author_short":["Duron, E.","Funalot, B.","Brunel, N.","Coste, J.","Quinquis, L.","Viollet, C.","Belmin, J.","Jouanny, P.","Pasquier, F.","Treluyer, J.","Epelbaum, J.","le Bouc, Y.","Hanon, O."],"bibdata":{"bibtype":"article","type":"article","title":"Insulin-like growth factor-I and insulin-like growth factor binding protein-3 in Alzheimer's disease","volume":"97","issn":"1945-7197","doi":"10.1210/jc.2012-2063","abstract":"CONTEXT: Few large studies have been conducted to assess the relationship between circulating IGF and late-life cognition. OBJECTIVE: The aim of the study was to assess the relationship between IGF-I and IGF binding protein-3 (IGFBP-3) serum levels and cognitive impairment, including Alzheimer's disease (AD). METHODS: In this multicentric cross-sectional study, 694 elderly subjects (218 men, 476 women; 78.6 ± 6.7 yr old) were included; 481 had memory complaints and were diagnosed, after comprehensive cognitive assessment, with AD (n = 224) or mild cognitive impairment (MCI) (n = 257). The control group was comprised of 213 subjects without memory complaint and with normal cognition (recruited among patients' caregivers). IGF-I and IGFBP-3 serum levels were determined by ELISA. RESULTS: IGF-I and IGFBP-3 serum levels were significantly associated with cognitive status in men (IGF-I, 137 ± 69 ng/ml for AD vs. 178 ± 88 ng/ml for MCI and 172 ± 91 ng/ml for controls, P = 0.01; IGFBP-3, 3675 ± 1542 ng/ml for AD vs. 4143 ± 1828 ng/ml for MCI and 4488 ± 1893 ng/ml for controls, P = 0.04). In women, IGFBP-3 was significantly associated with cognitive status (3781 ± 1351 ng/ml for AD vs. 4190 ± 1408 ng/ml for MCI and 4390 ± 1552 ng/ml for controls; P \\textless 0.001), but no significant differences between groups for IGF-I occurred. After adjustment for confounding variables (age, educational level, body mass index, diabetes, apolipoprotein E ε4 status), logistic regression indicated that IGF-I [odds ratio (95% confidence interval) = 0.48 (0.26-0.88)] and IGFBP-3 [odds ratio (95% confidence interval) = 0.71 (0.52-0.97)] serum levels were independently associated with AD in men, but not in women. CONCLUSIONS: We report a significant association between low IGF-I and IGFBP-3 serum levels and AD in men, but not in women.","language":"eng","number":"12","journal":"The Journal of Clinical Endocrinology and Metabolism","author":[{"propositions":[],"lastnames":["Duron"],"firstnames":["Emmanuelle"],"suffixes":[]},{"propositions":[],"lastnames":["Funalot"],"firstnames":["Benoît"],"suffixes":[]},{"propositions":[],"lastnames":["Brunel"],"firstnames":["Nadège"],"suffixes":[]},{"propositions":[],"lastnames":["Coste"],"firstnames":["Joel"],"suffixes":[]},{"propositions":[],"lastnames":["Quinquis"],"firstnames":["Laurent"],"suffixes":[]},{"propositions":[],"lastnames":["Viollet"],"firstnames":["Cécile"],"suffixes":[]},{"propositions":[],"lastnames":["Belmin"],"firstnames":["Joel"],"suffixes":[]},{"propositions":[],"lastnames":["Jouanny"],"firstnames":["Pierre"],"suffixes":[]},{"propositions":[],"lastnames":["Pasquier"],"firstnames":["Florence"],"suffixes":[]},{"propositions":[],"lastnames":["Treluyer"],"firstnames":["Jean-Marc"],"suffixes":[]},{"propositions":[],"lastnames":["Epelbaum"],"firstnames":["Jacques"],"suffixes":[]},{"propositions":["le"],"lastnames":["Bouc"],"firstnames":["Yves"],"suffixes":[]},{"propositions":[],"lastnames":["Hanon"],"firstnames":["Olivier"],"suffixes":[]}],"month":"December","year":"2012","pmid":"23015654","keywords":"Aged, Alzheimer Disease, Humans, Cognition, Female, Male, Neuropsychological Tests, Cross-Sectional Studies, Aged, 80 and over, Apolipoproteins E, Genotype, Memory, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I","pages":"4673–4681","bibtex":"@article{duron_insulin-like_2012,\n\ttitle = {Insulin-like growth factor-{I} and insulin-like growth factor binding protein-3 in {Alzheimer}'s disease},\n\tvolume = {97},\n\tissn = {1945-7197},\n\tdoi = {10.1210/jc.2012-2063},\n\tabstract = {CONTEXT: Few large studies have been conducted to assess the relationship between circulating IGF and late-life cognition.\nOBJECTIVE: The aim of the study was to assess the relationship between IGF-I and IGF binding protein-3 (IGFBP-3) serum levels and cognitive impairment, including Alzheimer's disease (AD).\nMETHODS: In this multicentric cross-sectional study, 694 elderly subjects (218 men, 476 women; 78.6 ± 6.7 yr old) were included; 481 had memory complaints and were diagnosed, after comprehensive cognitive assessment, with AD (n = 224) or mild cognitive impairment (MCI) (n = 257). The control group was comprised of 213 subjects without memory complaint and with normal cognition (recruited among patients' caregivers). IGF-I and IGFBP-3 serum levels were determined by ELISA.\nRESULTS: IGF-I and IGFBP-3 serum levels were significantly associated with cognitive status in men (IGF-I, 137 ± 69 ng/ml for AD vs. 178 ± 88 ng/ml for MCI and 172 ± 91 ng/ml for controls, P = 0.01; IGFBP-3, 3675 ± 1542 ng/ml for AD vs. 4143 ± 1828 ng/ml for MCI and 4488 ± 1893 ng/ml for controls, P = 0.04). In women, IGFBP-3 was significantly associated with cognitive status (3781 ± 1351 ng/ml for AD vs. 4190 ± 1408 ng/ml for MCI and 4390 ± 1552 ng/ml for controls; P {\\textless} 0.001), but no significant differences between groups for IGF-I occurred. After adjustment for confounding variables (age, educational level, body mass index, diabetes, apolipoprotein E ε4 status), logistic regression indicated that IGF-I [odds ratio (95\\% confidence interval) = 0.48 (0.26-0.88)] and IGFBP-3 [odds ratio (95\\% confidence interval) = 0.71 (0.52-0.97)] serum levels were independently associated with AD in men, but not in women.\nCONCLUSIONS: We report a significant association between low IGF-I and IGFBP-3 serum levels and AD in men, but not in women.},\n\tlanguage = {eng},\n\tnumber = {12},\n\tjournal = {The Journal of Clinical Endocrinology and Metabolism},\n\tauthor = {Duron, Emmanuelle and Funalot, Benoît and Brunel, Nadège and Coste, Joel and Quinquis, Laurent and Viollet, Cécile and Belmin, Joel and Jouanny, Pierre and Pasquier, Florence and Treluyer, Jean-Marc and Epelbaum, Jacques and le Bouc, Yves and Hanon, Olivier},\n\tmonth = dec,\n\tyear = {2012},\n\tpmid = {23015654},\n\tkeywords = {Aged, Alzheimer Disease, Humans, Cognition, Female, Male, Neuropsychological Tests, Cross-Sectional Studies, Aged, 80 and over, Apolipoproteins E, Genotype, Memory, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I},\n\tpages = {4673--4681}\n}\n\n","author_short":["Duron, E.","Funalot, B.","Brunel, N.","Coste, J.","Quinquis, L.","Viollet, C.","Belmin, J.","Jouanny, P.","Pasquier, F.","Treluyer, J.","Epelbaum, J.","le Bouc, Y.","Hanon, O."],"key":"duron_insulin-like_2012","id":"duron_insulin-like_2012","bibbaseid":"duron-funalot-brunel-coste-quinquis-viollet-belmin-jouanny-etal-insulinlikegrowthfactoriandinsulinlikegrowthfactorbindingprotein3inalzheimersdisease-2012","role":"author","urls":{},"keyword":["Aged","Alzheimer Disease","Humans","Cognition","Female","Male","Neuropsychological Tests","Cross-Sectional Studies","Aged","80 and over","Apolipoproteins E","Genotype","Memory","Insulin-Like Growth Factor Binding Protein 3","Insulin-Like Growth Factor I"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://github.com/leromela/bibtex/blob/main/Centre_Memoire.bib?raw=true","creationDate":"2021-03-09T16:04:10.306Z","downloads":0,"keywords":["aged","alzheimer disease","humans","cognition","female","male","neuropsychological tests","cross-sectional studies","aged","80 and over","apolipoproteins e","genotype","memory","insulin-like growth factor binding protein 3","insulin-like growth factor i"],"search_terms":["insulin","growth","factor","insulin","growth","factor","binding","protein","alzheimer","disease","duron","funalot","brunel","coste","quinquis","viollet","belmin","jouanny","pasquier","treluyer","epelbaum","le bouc","hanon"],"title":"Insulin-like growth factor-I and insulin-like growth factor binding protein-3 in Alzheimer's disease","year":2012,"dataSources":["j489FYr48Mag45aCq"]}